Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
A phase 1/2 trial of BGB-16673 in hodgkin lymphoma and non-hodgkin lymphoma, run by BeiGene, now recruiting.
Overview
Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader is a phase 1/2 interventional study registered as NCT05294731 by BeiGene, with 146 participants planned, started 2022-05-06 and due to reach its primary completion in 2029-01-31. Interventions recorded: BGB-16673. Conditions listed: B-cell Malignancy, Non-Hodgkin Lymphoma, Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Shares BGB-16673, BeOne Medicines (formerly BeiGene), Mantle cell lymphoma, Follicular lymphoma.
- TrialA Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
Shares Mantle cell lymphoma, Follicular lymphoma, Non-Hodgkin lymphoma (all types), Hodgkin lymphoma.
- TrialA Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantl
Shares BeOne Medicines (formerly BeiGene), Mantle cell lymphoma, Non-Hodgkin lymphoma (all types), Hodgkin lymphoma.
- TrialGene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Shares Mantle cell lymphoma, Follicular lymphoma, Non-Hodgkin lymphoma (all types).
- TrialSurovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
Shares Follicular lymphoma, Non-Hodgkin lymphoma (all types), Hodgkin lymphoma.
- TermLugano classification / Ann Arbor staging
Shares Mantle cell lymphoma, Follicular lymphoma, Hodgkin lymphoma.
- TrialStudy of BGB-11417 Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma
Shares BeOne Medicines (formerly BeiGene), Mantle cell lymphoma.
- CollectionLymphoma Research Foundation (LRF)
Shares Mantle cell lymphoma, Follicular lymphoma, Hodgkin lymphoma.